Intuitive Surgical (ISRG) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
19 Jan, 2026Executive summary
Q3 2024 revenue rose 17% year-over-year to $2.04 billion, driven by 18% growth in da Vinci procedures and 73% growth in Ion procedures, with 379 da Vinci systems placed and the installed base reaching 9,539 systems globally, up 15% year-over-year.
Net income attributable to the company was $565 million ($1.56/share GAAP), up from $416 million ($1.16/share) last year; non-GAAP net income was $669 million ($1.84/share), up from $524 million ($1.46/share).
The da Vinci 5th generation system launched in March, with 110 placements in Q3 and regulatory clearances in the U.S. and South Korea; over 12,000 procedures completed in six months.
Ion and SP platforms continue to expand, with Ion installed base up 50% to 736 systems and procedure growth of 73%; first Ion placements in China and expanded early launch in Europe.
Digital tools and analytics adoption increased, with over 14,000 active My Intuitive app users and 2,000 ORs enabled with Intuitive Hub.
Financial highlights
Q3 2024 total revenue: $2.04 billion (+17% YoY); pro forma gross margin was 69.1%, GAAP gross margin 67.4%.
Pro forma net income was $669 million ($1.84/share); GAAP net income was $565 million ($1.56/share).
Cash and investments ended at $8.31 billion, up $628 million sequentially and $0.97 billion from December 2023.
System average selling price was $1.51M, up from $1.4M last year; leasing represented 58% of Q3 placements.
Free cash flow for nine months ended September 30, 2024, was $1.59 billion.
Outlook and guidance
Full-year 2024 procedure growth guidance raised to 16%-17%; pro forma gross margin expected between 68.5%-69% of net revenue.
Pro forma operating expense growth forecasted at 10%-12% for 2024; pro forma income tax rate expected at 22%-23%.
Other income (mainly interest) expected between $325M-$345M; capital expenditures estimated at $1B-$1.2B.
Management expects continued growth in procedure volumes, with U.S. and OUS markets both contributing.
Customers remain cautious in capital spending due to staffing shortages, inflation, and macroeconomic pressures.
Latest events from Intuitive Surgical
- Board recommends approval of all annual meeting proposals, including director elections and compensation.ISRG
Proxy Filing13 Mar 2026 - Shareholders to vote on board, pay, auditor, and equity plan amid strong growth and governance.ISRG
Proxy Filing13 Mar 2026 - Board elections, strong financial growth, and all management proposals approved; shareholder proposals rejected.ISRG
AGM 20253 Feb 2026 - Q2 revenue up 14% to $2.01B–$2.2B, driven by strong procedure and system growth.ISRG
Q2 20243 Feb 2026 - Strong 2025 growth and da Vinci 5 adoption drive continued expansion into 2026.ISRG
Q4 202522 Jan 2026 - Da Vinci 5 launch drives strong placements and positive feedback, supporting robust financial outlook.ISRG
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Record growth, innovation, and digital expansion set the stage for global priorities in 2026.ISRG
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Da Vinci 5 launch, innovation, and global growth drive momentum in minimally invasive care.ISRG
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 revenue up 25% with strong da Vinci growth; 2025 outlook cautious on margins.ISRG
Q4 20249 Jan 2026